A PHASE III, RANDOMIZED, OPEN-LABEL, NON-INFERIORITY COMPARATIVE STUDY BETWEEN SERETIDE® 50/250 ΜG and SALMETEROL/FLUTICASONE SINGLE INHALATION CAPSULE 50/250 ΜG EUROFARMA in PATIENTS with ASTHMA
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 334
- 试验地点
- 6
- 主要终点
- Forced expiratory volume in 1 second (FEV1) at the final visit.
研究概览
简要总结
The primary objective will be to compare the formulations regarding their impact on the pulmonary function of persistent asthma patients and the secondary objective will be the clinical control of the disease's symptoms.
详细描述
The primary objective will be to compare the formulations regarding their impact on the pulmonary function of persistent asthma patients and the secondary objective will be the clinical control of the disease's symptoms.
Primary endpoint: Forced expiratory volume in 1 second (FEV1) at the final visit.
Secondary endpoints: Expiratory Flow Peak (EFP), symptoms score, FEV1 throughout the study, use of rescue medication, compliance with inhaler use, inhaler acceptance and preference, and frequency of the observed adverse events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign the ICF
- •≥ 12 years old
- •Have a persistent asthma diagnosis, as per GINA classification,18 with symptoms for at least 6 months and clinically stable for at least 1 month with the ACQ-7 test (please see Appendix C) ≤ 3.0
- •Current use of inhaled corticosteroid (up to 1000 µg of beclomethasone dipropionate) whether combined or not with long-term β2-adrenergics and relief medication (salbutamol or equivalent)
- •Initial FEV1 of at least 40% of the normal value expected
- •Blood cortisol evaluation within the normal limits.
排除标准
- •Use of oral or parenteral corticosteroid within the last 3 previous months to the study
- •Hospitalization needed due to asthma within the last 3 previous months to the study
- •Active smokers, defined as the consumption of cigarettes, pipes, cigars or any other form of smoking in any amount within the last 3 months
- •Presence of severe co-morbidities, such as cardiovascular, renal, liver, neurological, neoplastic, hematological, infectious, dermatological, neurological or psychiatric disease or chronic respiratory disease other than asthma
- •Recent (<6 months) or expected participation during this study in other clinical trials involving drugs of any nature or in studies consisting of any - Intolerance or allergy to any component of the drugs evaluated in the study
- •Pregnant or lactating women
- •Chronic use of routine β-blockers, orally or intravenously, including ophthalmic solutions.
研究组 & 干预措施
Salmeterol/Fluticasone
干预措施: Salmeterol/Fluticasone (Drug)
Seretide
干预措施: Seretide (Drug)
结局指标
主要结局
Forced expiratory volume in 1 second (FEV1) at the final visit.
次要结局
- Expiratory Flow Peak (EFP)